LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

AI Image Analysis Module Detects Cancers at the Time of Surgery

By LabMedica International staff writers
Posted on 26 May 2022
Image: NIO Laser Imaging System (Photo courtesy of Invenio Imaging)
Image: NIO Laser Imaging System (Photo courtesy of Invenio Imaging)

A new image analysis module based on deep learning allows neurosurgeons to identify areas of cancer infiltration in patients undergoing primary treatment of a diffuse glioma, providing cancer detection where they really need it and dramatically improving brain tumor surgery.

Invenio Imaging Inc.’s (Santa Clara, CA, USA) NIO Laser Imaging System uses Stimulated Raman Histology to image unprocessed tissue specimen without sectioning or staining, enabling histologic evaluation outside the laboratory. It has been used in over 2000 brain tumor procedures across multiple institutions in the US and in Europe. SRH allows three-dimensional imaging of thick specimens using optical sectioning and relies on laser spectroscopy to interrogate the chemical composition of the sample. As such, it does not require physical sectioning, (e.g. with a microtome on frozen or paraffin-embedded tissue) or dye staining, and it allows optical imaging of fresh tissue specimens with minimal tissue preparation.

In contrast to other laser spectroscopy techniques, SRH is unique in that it performs a spectroscopic measurement at each pixel and displays the results as a pseudo-color image, instead of a point spectrum. The NIO Laser Imaging System uses a high numerical aperture objective with 25x magnification and a 0.5mm scan width. Larger areas up to 10mm x 10mm can then be acquired by stitching multiple fields of view in a fully automated process. NIO images are natively digital and can be shared with existing IT infrastructure via a vendor-neutral DICOM interface. The NIO Glioma Reveal image analysis module now adds immediate decision support to the NIO Laser Imaging System by allowing the imaging of multiple samples from the resection cavity. Invenio has received the CE Mark for the NIO Glioma Reveal image analysis module, allowing neurosurgeons in the EU to use it to inform intraoperative decisions.

"By streamlining intraoperative tissue imaging, the NIO Laser Imaging System allows the imaging of multiple samples from the resection cavity. The NIO Glioma Reveal image analysis module now adds immediate decision support", said Chris Freudiger, PhD, co-founder and CTO of Invenio Imaging.

"Glioma Reveal provides cancer detection where we really need it, dramatically improving brain tumor surgery," added Prof. Dr. Jürgen Beck, Chair of Neurosurgery at the University of Freiburg.

"Applying reliable artificial intelligence to digital pathology appears to me, as a surgeon, to be the missing piece in the puzzle of rapid intraoperative histology-based decision-making," said Asst. Prof. Dr. Volker Neuschmelting, Vice-Chair of Neurosurgery at the University of Cologne.

"The NIO Laser Imaging System can also be combined with other important imaging techniques such as 5-ALA fluorescence to further improve brain tumor detection during surgery," explained Prof. Dr. Georg Widhalm, neurosurgeon at the University of Vienna.

Related Links:
Invenio Imaging Inc.

New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Hemodynamic System Monitor
OptoMonitor
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more